Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04978584
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- ADC Therapeutics S.A.
- Registration Number
- NCT04974996
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 732
- Registration Number
- NCT04951986
- Locations
- 🇿🇦
Mitchells Plain Hospital, Mitchells PLain, Cape Town, Western Cape, South Africa
🇿🇦Khayelitsha Hospital, c/o Steve Biko and Walter Sisulu Drives, Khayelitsha, Cape Town, Western Cape, South Africa
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT04947254
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
- Conditions
- Interventions
- Biological: RituximabDrug: EtoposideBiological: CopanlisibDrug: CyclophosphamideDrug: DoxorubicinDrug: VincristineDrug: PrednisoneDiagnostic Test: ECHODiagnostic Test: EKGDiagnostic Test: MRI BrainDiagnostic Test: 18F-FDG - PETDiagnostic Test: CT ScanProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDiagnostic Test: Lumbar Puncture (LP)
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 8
- Registration Number
- NCT04933617
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2022-11-07
- Target Recruit Count
- 289
- Registration Number
- NCT04922567
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
The Clinical Features and Pregnancy Outcomes of CTD Patients
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 126
- Registration Number
- NCT04918524
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-01-11
- Target Recruit Count
- 8
- Registration Number
- NCT04918147
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Mayo Clinic: Pulmonary and Critical Care Medicine, Rochester, Minnesota, United States
🇺🇸Emory Healthcare, Atlanta, Georgia, United States
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT04907227
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University ( Site 1319), Xiamen, Fujian, China
🇨🇳Hunan Cancer Hospital ( Site 1320), Changsha, Hunan, China
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine ( Site 1309), Hangzhou, Zhejiang, China
Selective CD28 Blockade in Renal Transplant Recipients
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.